| |
All
|
Non-CP/non- candidemia
|
Suspected CP
|
Non-CP/ candidemia
|
P
|
|---|
|
Number
|
31
|
18
|
9
|
4
| |
|
Age, year
|
66.4 ± 16.6
|
65.3 ± 18.5
|
66.9 ± 16.5
|
70.3 ± 6.2
|
0.971a
|
|
Sex, male (%)
|
20 (64.5)
|
11 (61.1)
|
6 (66.7)
|
3 (75.0)
|
0.860b
|
|
APACHE II at ICU admission
|
22.4 ± 5.2
|
22.3 ± 5.2
|
21.1 ± 4.2
|
25.3 ± 6.9
|
0.583a
|
|
APACHE II on enrolled day
|
24.2 ± 4.8
|
23.2 ± 5.0
|
25.1 ± 3.9
|
27.0 ± 5.3
|
0.316a
|
|
Initial reasons for MV (%)
|
|
Post-surgery
|
7 (22.6%)
|
3 (16.7)
|
2 (22.2)
|
2 (50.0)
|
0.353b
|
|
Pneumonia
|
24 (77.4%)
|
15 (83.3)
|
7 (77.8)
|
2 (50.0)
|
0.353b
|
|
Reasons for BAL (%)
|
|
Non-responding pneumonia
|
18 (58.1)
|
9 (50.0)
|
7 (77.8)
|
2 (50)
|
0.363b
|
|
Newly developed infiltration
|
13 (41.9)
|
9 (50.0)
|
2 (22.2)
|
2 (50)
|
0.363b
|
|
Host factors (%)
|
|
Recent neutropenia
|
10 (32.3)
|
5 (27.8)
|
2 (22.2)
|
3 (75.0)
|
0.141b
|
|
Prolonged steroid use
|
16 (51.6)
|
10 (55.6)
|
5 (55.6)
|
1 (25.0)
|
0.521b
|
|
Immunosuppressants
|
5 (16.1)
|
3 (16.7)
|
2 (22.2)
|
0
|
0.600b
|
|
MV days
|
24.2 ± 12.5
|
23.7 ± 14.9
|
22.9 ± 9.4
|
29.3 ± 5.7
|
0.129a
|
|
ICU stay, days
|
27.8 ± 11.9
|
28.0 ± 14.4
|
26.6 ± 9.2
|
30.0 ± 4.3
|
0.494a
|
|
ICU mortality (%)
|
14 (45.2)
|
6 (33.3)
|
5 (55.6)
|
3 (75.0)
|
0.241b
|
|
Radiographic manifestationsc (%)
|
|
Halo sign
|
1 (3.2)
|
0
|
1 (11.1)
|
0
|
0.283b
|
|
Single/multiple nodules
|
11 (35.5)
|
3 (16.7)
|
7 (77.8)
|
1 (25.0)
|
0.007b
|
|
Cavitary lesion
|
6 (19.4)
|
3 (16.7)
|
3 (33.3)
|
0
|
0.338b
|
|
GGO/infiltration
|
29 (93.5)
|
17 (94.4)
|
8 (88.9)
|
4 (100)
|
0.732b
|
|
Mycological evidence of yeast (%)
|
|
TBLBd,e
|
4 (12.9)
|
0
|
4 (44.5)
|
0
|
< 0.001b
|
|
BALe
|
13 (41.9)
|
4 (22.2)
|
8 (88.9)
|
1 (25.0)
|
0.003b
|
|
TA fungal culture
|
14 (45.2)
|
7 (38.9)
|
6 (66.7)
|
1 (25.0)
|
0.269b
|
|
BAL fungal culture
|
13 (41.9)
|
5 (27.8)
|
8 (88.9)
|
0
|
0.002b
|
- Data are presented with means ± standard deviations
-
CP Candida pneumonia, APACHE acute physiology and chronic health evaluation, MV mechanical ventilation, BAL bronchoalveolar lavage, GGO ground glass opacity, TBLB transbronchial lung biopsy, TA endotracheal aspirate, BAL bronchoalveolar lavage fluid
-
aKruskal-Wallis test
-
bFisher’s exact test
-
cEach single patient could have more than one type of radiographic manifestation
-
dA total of 19 patients underwent TBLB, including 11 in non-CP/non-candidemia, 7 in suspected CP, and 1 in non-CP/candidemia
-
eFungal staining was applied using Grocott-Gomori methenamine silver stain in BAL and Periodic Acid-Schiff stain in TBLB
